以临床及经济价值为核心的药械（疫苗）可及性研究
创新医疗器械可及性研究
核心内容：基于不同创新药械的临床价值，构建决策分析模型，模拟患者治疗的总成本及健康结局，遴选具有经济性的防治策略。
学术价值：助力创新药械定价管理与医保准入，提升患者可负担性；研究成果发表于心血管领域权威期刊Circulation子刊。
医保目录药品可及性研究
核心内容：基于国家药管平台药品采购数据，探究我国各省国谈肿瘤药及罕见病药品公平可及的影响因素，评估国家集采政策下药品价格的传导机制。
学术价值：促进肿瘤及罕见病患者用药公平可及；研究成果被国家医保局价采中心采纳应用，感谢信中充分肯定发挥的专家智库作用，并邀请撰写指南；与西安市医保局签署合作框架，作为骨干 成员，共同承担国家医保局委托的基于真实世界数据的医保目录内药品退出机制研究。
疫苗接种可及性研究
核心内容：构建儿童家长疫苗犹豫理论模型，开发疫苗犹豫量表并构建常模标准；基于行为经济学理论提出疫苗接种干预策略并评价其施测效果。
学术价值：提升重点人群疫苗接种率；研究成果被国家免疫规划技术工作组撰写的《中国流感疫苗预防接种技术指南》引用；作为陕西地区负责人，参与国家疾控局组织的老人新冠疫苗接种意愿调查。
第一/通讯作者20余篇，H-Index 18，被引1100+，主要发表于Lancet Global Health、American Journal of Preventive Medicine、PharmacoEconomics、Vaccine等期刊。
近年发表的学术论文如下：
1. Yao X, Fu M, Peng J, Feng D, Ma Y, Wu Y, Feng L, Fang Y, Jiang M*. Socioeconomic disparities in childhood vaccine hesitancy among parents in China: The mediating role of social support and health literacy. Human Vaccines & Immunotherapeutics. 2025;21(1):2444008.
2. Peng J, Zheng X, Jiang M*, Yao X, Ma Y, Fu M, Ma T, Shang X, Yan Y*, Thourani VH*, Fang Y*. Cost-Effectiveness of Aortic Valve Replacement in Low- and Intermediate-Risk Chinese Patients With Severe Aortic Stenosis. Circulation: Cardiovascular Quality and Outcomes. 2025;18(4):e010858.
3. Yao X, Fu M, Peng J, Feng D, Ma Y, Wu Y, Feng L, Fang Y, Jiang M*. Socioeconomic disparities in childhood vaccine hesitancy among parents in China: The mediating role of social support and health literacy. Human Vaccines & Immunotherapeutics. 2025;21(1):2444008.
4. Zhou L, Jiang M, Duan R, Zuo F, Li Z, Xu S*. Barriers and Implications of 5G Technology Adoption for Hospitals in Western China: Integrated Interpretive Structural Modeling and Decision-Making Trial and Evaluation Laboratory Analysis. JMIR mHealth and uHealth. 2024;12:e48842.
5. Jiang M, Zhang H, Yao X, Wang Y, Lai X, Fang H*. Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China. Vaccine. 2024;42(25):126150.
6. Yao X, Peng J, Ma Y, Fu M, Fang Y*, Fang H*, Jiang M*. Development of a vaccine hesitancy scale for childhood immunization in China. Vaccine. 2023;41(46):6870–6877.
7. Ma Y, Peng J, Yao X, Feng L, Shi X, Jiang M*. Access to anticancer medicines in public hospitals of Northwestern China. Frontiers in Public Health. 2023;11:1182617.
8. Jiang M, Yao X, Peng J, Feng L, Ma Y, Shi X, Fang Y, Fang H. Cost-effectiveness of recombinant zoster vaccine for adults aged ≥50 years in China. American Journal of Preventive Medicine. 2023;65(5):818–826.
9. Gong Y, Yao X, Peng J, Ma Y, Fang Y, Yan K, Jiang M*. Cost-effectiveness and health impacts of different influenza vaccination strategies for children in China. American Journal of Preventive Medicine. 2023;65(1):155–164.
10. Ma Y, Fang Y, Feng L, Zhao M, Peng J, Yao X, Jiang M. 2019年—2021年陕西省特药目录中抗肿瘤药可及性研究. 中国医疗保险. 2022;(9):110–115.
11. Zhou H, Nie X, Jiang M, Dong W*. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China. Journal of Clinical Pharmacy and Therapeutics. 2022;47(4):523–530.
12. Fang H*, Chen C, Fang Y, He X, Hou Z, Jiang M, Jiang Y, Li S, Liu Y, Sui BY, Sun Q, Wu J, Xu T, Yang J, Yin Z, Ying X, Yuan B, Zheng H, Zheng Y. A guideline for economic evaluations of vaccines and immunization programs in China. Human Vaccines & Immunotherapeutics. 2022;18(6):2132802.
13. Yang R, Kabba JA, Yao X, Yang C, Chang J, Ji W, Jiang M, Zhao M, Wen J*, Fang Y*. Current situation and future development of the biopharmaceutical industry in China: A mixed-method study. Frontiers in Pharmacology. 2022;13:911165.
14. Jiang M*, Yao X, Li P, Fang Y, Feng L, Hayat K, Shi X, Gong Y, Peng J, Atif N. Impact of video-led educational intervention on uptake of influenza vaccine among the elderly in western China: a community-based randomized controlled trial. BMC Public Health. 2022;22:1128.
15. Jiang M#*, Gong Y#, Fang Y, Yao X, Feng L, Zhu S, Peng J, Shi X. Parental Preferences of Influenza Vaccination for Children in China: A National Survey with a Discrete Choice Experiment. International Journal of Environmental Research and Public Health. 2022;19(4):2145.（# 共一）
16. Jiang M, Feng L, Wang W, Gong Y, Ming WK, Hayat K, Li P, Gillani AH, Yao X, Fang Y*. Knowledge, attitudes, and practices towards influenza among Chinese adults during the epidemic of COVID-19. Human Vaccines & Immunotherapeutics. 2021;17(5):1412–1419.
17. Jiang M, Li P, Yao X, Hayat K, Gong Y, Zhu S, Peng J, Shi X, Pu Z, Huang Y, Fang Y. Preference of influenza vaccination among the elderly population in Shaanxi province, China. Human Vaccines & Immunotherapeutics. 2021;17(9):3119–3125.
18. Li P#, Hayat K#, Jiang M#, Pu Z, Yao X, Zou Y, Lambojon K, Huang Y, Hua J, Xiao H, Du F, Shi L, Zhai P, Ji W, Feng Z, Gong Y, Fang Y*. Impact of video-led educational intervention on the uptake of influenza vaccine among adults aged 60 years and above in China: a study protocol for a randomized controlled trial. BMC Public Health. 2021;21:222.（# 共一）
19. Jiang M*, Li P, Wang W, Zhao M, Atif N, Zhu S, Fang Y. Cost-effectiveness of Quadrivalent Versus Trivalent Influenza Vaccine for Elderly Population in China. Vaccine. 2020;38(5):1057–1064.
20. Ye D, Yan K, Zhang H, Liu S, Yang C, Jiang M, Zhao M, Ji W, Fang Y*. A Survey of Knowledge, Attitudes and Practices Concerning Antibiotic Prescription for Upper Respiratory Tract Infections Among Pediatricians in 2018 in Shaanxi Province, China. Expert Review of Anti-infective Therapy. 2020;18(9):927–936.
21. Li Z, Feng Q, Kabba JA, Yang C, Chang J, Jiang M, Zhao M, Yu J, Xu S, Li Q, Zhai P, Fang Y*. Prices, availability and affordability of insulin products: a cross-sectional survey in Shaanxi Province, western China. Tropical Medicine and International Health. 2019;24(1):43–52.
22. Jiang M, Li P, You JHS, Zheng X, Deng J, Zhao M, Feng L, Fang Y*. Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. PLOS ONE. 2019;14(12):e0224580.
23. Xing N, Cheung WY, Jiang M, You JHS*. Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis. American Journal of Infection Control. 2019;47(11):1302–1308.
24. Hong D#, Si L#, Jiang M, Shao H, Ming WK, Zhao Y, Li Y, Shi L*. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics. 2019;37(6):777–818.（# 共一）
25. Aziz MM, Jiang M, Masood I, Chang J, Shan Z, Raza MA, Ji W, Yang C, Fang Y*. Patients’ Anticipation for the Pharmacies of Rural Communities: A Qualitative Study from Pakistan. International Journal of Environmental Research and Public Health. 2019;16(1):143.
26. Aziz MM, Jiang M, Masood I, Chang J, Shan Z, Raza MA, Ji W, Yang C, Fang Y*. Patients’ Anticipation for the Pharmacies of Rural Communities: A Qualitative Study from Pakistan. International Journal of Environmental Research and Public Health. 2019;16(1):143.
27. Yan K, Xue M, Ye D, Yang C, Chang J, Jiang M, Zhao M, Zhang H, Fang Y*. Antibiotic prescribing practices in secondary and tertiary hospitals in Shaanxi province, western China, 2013–2015. PLOS ONE. 2018;13(12):e0207229.
28. Jiang M, Leung NH, Ip M, You JHS*. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection. PLOS ONE. 2018;13(7):e0201539.
29. Chang J#, Ye D#, Lv B, Jiang M, Zhu S, Yan K, Tian Y, Fang Y*. Sale of antibiotics without a prescription at community pharmacies in urban China: a multicentre cross-sectional survey. Journal of Antimicrobial Chemotherapy. 2017;72(4):1235–1242.（# 共一）
参编学术指南
《精神疾病药品临床综合评价技术指南》 2025-12-18
《中国药物经济学评价指南（2025中英双语版）》2025-09-01
《中国疫苗经济学评价指南》2022-05-13
参编专家共识
《卫生技术评估中疗效与安全性间接比较证据生成专家共识（2026）》2026-08-03
《临床试验加载药物经济学评价中国专家共识》2024-10-24
《西北五省药品集采科学管理专家共识》2022-08-24
参编教材
《药物经济学》高等教育出版社 2026
《药学概论》科学出版社 2025
1. [2025年] 基于真实世界证据微观仿真模拟的脑血管病非药物治疗及创新器械卫生经济学评价研究；项目来源单位：国家卫生健康委卫生科技发展研究中心；
2. [2025年] 零售药店药品价格治理效能评估与优化路径研究；项目来源单位：上海强生制药有限公司
3. [2025年] 中国肥胖症疾病负担及政策保障研究；项目来源单位：诺和诺德（上海）医药贸易有限公司
4. [2025年] 基于文献证据与真实世界数据的精神类药品临床综合评价主题遴选机制研究；项目来源单位：国家心理健康和精神卫生防治中心
5. [2024年] 西安市治疗性医疗机构制剂纳入基本医疗保险支付范围研究；项目来源单位：西安市医疗保障局
6. [2024年] 晚期乳腺癌精准治疗的预算影响分析模型研究；项目来源单位：阿斯利康投资（中国）有限公司
7. [2024年] 原发性高胆固醇血症患者降脂质量的成本效果分析与预算影响分析研究；项目来源单位：赛诺菲（中国）投资有限公司
8. [2024年] 基于医保准入分类机制的国谈药品药物经济学创新价值评估；项目来源单位：阿斯利康投资（中国）有限公司
9. [2024年] 基于药物基因组学检测的精准用药卫生经济学评估；项目来源单位：西安天隆科技有限公司
10.[2023年] 儿童疫苗犹豫监测技术与干预策略研究；项目来源：陕西省自然科学基金重点研发计划
11.[2023年] 西安市治疗性医疗机构制剂纳入基本医疗保险支付范围研究；项目来源单位：西安市医疗保障局
12.[2023年] 陕西省国谈抗肿瘤药供应保障对策研究；项目来源：陕西省哲学社会科学研究青年项目
13.[2023年] 原发性高胆固醇血症患者降脂质量的成本效果分析与预算影响分析研究；项目来源单位：赛诺菲（中国）投资有限公司
14.[2023年] 基于COM-B模型的儿童流感疫苗接种犹豫驱动机制与干预策略研究；项目来源：陕西省博士后基金一等资助
